Navigation Links
Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics

GAITHERSBURG, Md., July 22 /PRNewswire/ -- Sirnaomics, Inc. ( announced today that the company has received an SBIR (small business innovation research) grant from National Cancer Institute (NCI), National Institute of Health (NIH), for its novel siRNA therapeutics to treat lung cancer. Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to advancing RNA interference (RNAi) Technology for novel targeted therapeutic development. The company's multi-targeted siRNA therapeutic programs utilizing its nanoparticle-enhanced delivery technologies represent a unique approach for truly realizing the advantages of small interfering RNA (siRNA)-based drugs to treat various critical human diseases. Sirnaomics has successfully attracted grants from NIH and the State of Maryland.

RNAi has emerged as a fundamentally important biological phenomenon and as a versatile, powerful tool for biomedical research. RNAi plays a multifaceted role in molecular biology by silencing genes through chromatin remodeling, interfering with protein synthesis, and in its best-studied mode of action quashing gene expression by cleaving messenger RNA. Experimental applications of RNAi have spurred the exploration of gene function in basic research, drug discovery and clinical settings. The 2006 Nobel Prize for medicine and physiology and a number of corporate acquisitions and investments by Novartis, Merck, AstraZeneca, Roche and Takeda have injected billions of dollars into this novel technology and further fueled the enthusiasm for the great promise of siRNA therapeutic development. There are more than a dozen clinical trials currently ongoing for various types of therapeutic applications.

Sirnaomics' mission is to advance RNAi technology by using its proprietary multi-targeted siRNA cocktail design together with the company's nanoparticle-mediated siRNA delivery vehicles in the rapid delivery of novel therapeutics. The company's proprietary "Tri-Blocker" technology for multi-targeted siRNA cocktail design and "Snano" series of nanoparticle delivery systems enable its advanced RNAi therapeutic programs for treatment of various diseases including H1N1/H5N1 influenza A infection, scarless wound healing and several types of cancers.

"Receiving an SBIR grant again from NCI clearly demonstrates the scientific and business merits of our lung cancer therapeutic program using multi-targeted siRNA cocktails," said Dr. Patrick Y. Lu, the founder, President and CEO of the company, also the Principal Investigator of the grant proposal. "It is a successful extension of Sirnaomics product pipeline for siRNA therapeutics." Dr. Lu further emphasized that the grants from various Government agencies provided a sustainable funding resource to the company in addition to its corporate partnership deals and venture capital investments. "Funding from Government is uniquely important for an early stage company like Sirnaomics, especially in the current financial environment."

Sirnaomics, Inc. is a privately held Delaware corporation headquartered in Gaithersburg, Maryland, USA. Established by a group of leading scientists in the field of RNAi technology, the company has a mission of advancing RNAi technology for novel drug discovery and targeted therapeutics development. Members of the senior management team bring over 50 years of combined experience in the biopharmaceutical, financial and business management industries in both the US and China and the company has established a subsidiary in Suzhou, China to expand both its R&D capacity and potential market.

    George J. Ji
    Sirnaomics, Inc.
    401 Professional Drive, Suite 130
    Gaithersburg, MD 20879, USA
    301-740-1730 Phone
    301-740-1731 FAX

SOURCE Sirnaomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
2. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
3. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
4. TorreyPines Receives Notice of Delisting from Nasdaq Global Market
5. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
6. UCR physicist receives highest honor US government gives young scientists or engineers
7. Professor Fisher receives ASEEs Beer and Johnston Award
8. Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
9. Unisense FertiliTech A/S Receives CE Mark of Approval for EmbryoScope(TM) Embryo Monitoring System
10. WuXi PharmaTech Receives Award from BASF
11. AEterna Zentaris Receives US$10 Million from Institutional Investors
Post Your Comments:
(Date:11/24/2015)... Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ... Laurin , President and Chief Executive Officer of ProMetic, will ... 27 th Annual Healthcare Conference to be held at ... st , at 8.50am (ET) and ProMetic,s management ... The presentation will be available live via a webcast accessible ...
(Date:11/24/2015)... Va. , Nov. 24, 2015 ... focused on discovering drugs for metabolic disorders, announced ... to its Board of Directors (BOD). Mr. ... officer of Human Genome Sciences (HGS), and also ... Organization. Jim Powers , Chairman and ...
(Date:11/24/2015)... and NEW YORK , November 24, ... investment by Bristol-Myers Squibb in a European ... Bristol-Myers Squibb Company in which the companies will work ... immuno-oncology and other areas of unmet medical need. The collaboration ... LSP 5, the latest LSP fund. This is the first ...
(Date:11/24/2015)... -- According to two new studies, fewer men are having ... many doctors, scientists, and public health experts have been pushing ... tests being done, will there be more men dying of ... "Despite the efforts made in regards to early detection ... cause of death in men, killing approximately 27,500 men this ...
Breaking Biology Technology:
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces today ... its Board of Directors. --> ... recently retiring from the partnership at TPG Capital, one ... with over $140 Billion in revenue.  He founded and ... all the TPG companies, from 1997 to 2013.  In ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
(Date:11/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), the ... entry into the automotive market with a comprehensive and ... of consumer electronics human interface innovation. Synaptics, industry-leading touch ... the automotive industry and will be implemented in numerous ... , Japan , and ...
Breaking Biology News(10 mins):